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Background: 11q13 region is a frequently amplified locus in human malignancies. Among the genes located in
this region, FADD is one of the alleged driving genes. Because amplification is not generally confined to a single
gene and amplified genes may not show increased expression, we need to evaluate clinical significance of changes
occurring in 11q13 region to understand their roles in carcinogenesis. Therefore, we screened expressions of FADD
and closely located genes (PPFIA1 and TMEM16A) and evaluated the expressions to find clinical significance in
invasive ductal carcinoma of the breast.
Methods: Ninety-eight cases of invasive ductal carcinoma of the breast were collected. Using archival tissues resected
from the cases, we built a tissue microarray and used it in immunohistochemistry. We evaluated the association of FADD,
PPFIA1, and TMEM16A expression scores with clinicopathological parameters, including disease-free survival.
Results: FADD expression was associated with T stage (P = 0.046). The combined score of FADD, PPFIA1, and TMEM16A
gene expressions was associated with perineural invasion (P = 0.022). Although individual gene expressions of TMEM16A,
FADD, and PPFIA1 failed to show significant association with disease-free survival, combined gene expression scores did
show association with disease-free survival (P = 0.034).
Conclusions: FADD, TMEM16A, and PPFIA1 gene expressions as a whole were associated with disease-free survival in
breast cancer.
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Amplification is one of the activating mechanisms of
proto-oncogenes during carcinogenesis [1]. Among the
frequently amplified regions in human malignancies,
amplifications of 11q13 were found in breast cancers
[2-4], esophageal squamous cell carcinoma [5], and head
and neck cancers [6-9]. In this region, several genes were
located and the amplified region encompassed more
than one of the tested loci [3]. In addition, region q13 of
chromosome 11 was pointed out to have a high pene-
trance gene for breast cancer in the study of 19 non-
BRCA1/2 families [10]. However, amplification does not* Correspondence: suyoung@catholic.ac.kr
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unless otherwise stated.necessarily result in increased expression of the affected
gene. Taking into account that gene products rather than
the genes themselves are effector molecules controlling
biological behavior of the cells, we need to know the ex-
pression changes of the genes located in 11q13 and their
clinical significance to understand their contribution to
tumor cell behavior.
Among the genes located in the region of 11q13,
FADD was reported as a driver in the 11q13 amplicon in
laryngeal/pharyngeal cancer [11]. FADD is an adaptor
molecule interacting with many kinds of death receptors
and induces apoptosis by caspase-8 [12,13]. FADD ex-
pression was associated with metastasis in squamous cell
carcinoma of the head and neck [14] and poor prognosis
in oral squamous cell carcinoma [15] and lung adenocar-
cinoma [16]. Because the amplification of FADD doesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primary antibodies used in immunohistochemistry
Target Dilution ratio Host Clone Provider
PPFIA1 1:100 Rabbit Proteintech
(Chicago, IL, USA)
TMEM16A 1:1 Rabbit SP31 Abcam (Cambridge, UK)
FADD 1:10 Rabbit EP887Y Abcam
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which are in close proximity to FADD, may be ampli-
fied concomitantly. In addition, the BAC clone (RP11-
203 N8), which is used as a template when synthesizing
the fluorescence in situ hybridization (FISH) probe for
FADD, includes the regions of TMEM16A and PPFIA1.
Confirmation of amplification by FISH cannot differenti-
ate copy number alterations among the genes. The locus
encompassing these three genes is amplified in several
malignancies, including breast cancer [17].
TMEM16A is associated with activation of the calcium
dependent chloride channel and regulates cell proliferation
[18,19]. TMEM16A is considered to be proto-oncogenic
and increases tumor growth when overexpressed in gastro-
intestinal stromal tumors [20], and head and neck cancer
[18]. Previous reports claimed that the calcium chloride
channel influenced the growth of tumors and loss of
TMEM16A, leading to decrease in tumor size [18,21].
However, the mechanism of tumor growth by TMEM16A
overexpression is not known [22].
PPFIA1 is a member of the LAR protein-tyrosine
phosphatase-interacting protein family. PPFIA1 is amp-
lified in human breast cancers and promotes inva-
siveness of breast and cervical cancer cells [23]. Also,
PPFIA1 acts as a tumor suppressor and regulates cell
motility by interacting with ING4 [24]. When expres-
sion of PPFIA1 was reduced, invasiveness of head and
neck squamous cell carcinomas (HNSCC) was found to
increase [25].
Although TMEM16A, FADD and PPFIA1 are co-
amplified in many malignancies, the combined effect of the
three gene expressions has not been evaluated to date. To
understand the net effect of these three gene alterations, we
screened the gene expressions by immunohistochemistry
and analyzed the association with clinicopathological pa-
rameters, including disease-free survival.
Methods
Patients and tumor tissues
We collected 98 cases of invasive ductal carcinoma surgi-
cally resected at Uijeongbu Mary’s Hospital from 2002 to
2004. Patients’ age was between 29 and 77 (mean, 49.1)
years old. Forty-six cases were treated with adjuvant
chemotherapy and 33 cases received hormone therapy.
Adjuvant radiotherapy was given to 22 cases. Disease-free
survival data (11.0 to 103.3 months; mean, 61.9 months)
was available. The disease recurred in 21 cases and 7 cases
died of the disease. We selected representative archival tis-
sues resected from the cases and tissue microarray was
constructed using manual tissue arrayer, MTA-1 (Estigen
Tissue Science, Estonia). Human tissue acquisition and
its use followed the Institutional Review Board-approved
protocol (CUMC11U058) at the Catholic University of
Korea, School of Medicine.Immunohistochemistry
The immunohistochemical staining of breast cancer tis-
sue followed the previously reported protocol [26].
Briefly, tissue sections were cut in 4-μm thicknesses and
transferred to ProbeOn Plus slides (Fisher Scientific,
Pittsburgh, PA, USA). To minimize tissue loss during
boiling procedure and to get rid of excess paraffin on the
slides, tissues were incubated for two hours in a 56°C dry
chamber (Agilent Technologies, Santa Clara, CA, USA).
The sections were deparaffinized in xylene three times and
hydrated through 100%, 90%, 80%, 70% ethanol and Tris-
buffered saline (TBS, pH 7.4). To make the epitopes more
accessible to the primary antibodies used in the current
study, the tissues were boiled in 10 mM sodium citrate
buffer (pH 6.0) using a microwave for 20 minutes. To
quench endogenous peroxidase, we treated the tissues
with 3% hydrogen peroxide in PBS. The tissues were
incubated with the respective primary antibodies at 4°C
overnight (Table 1). After incubating the tissue with bi-
otinylated secondary antibody, diluted (1:50) ExtrAvidin
(Sigma-Aldrich, St. Louis, MO, USA) was used to amplify
signal intensity. For visualization, liquid DAB + substrate
chromogen system (Dako, Glostrup, Denmark) was used.
Scoring of immunohistochemical staining was divided
into three groups. Positive staining in less than 5% of
tumor cells was considered negative. Cases showing a
brown color in more than 50% of tumor cells were con-
sidered to be a strongly positive group. Cases showing
light brown color in more than 5% and dark brown color
in less than 50% of tumor cells were counted as a weakly
positive group [14,20].
Statistical analysis
Where appropriate, the Chi-square test or Fisher’s exact
test was used to evaluate association of immunoreac-
tivity with clinicopathologic parameters. For disease-
free survival analysis, Kaplan-Meier method and the
nonparametric log-rank test was used. We used R ver.
3.0.2 (R foundation, Vienna, Austria) for statistical tests
and their graphic presentations.
Results
Patient characteristics
Among 98 cases in total, 5 (5.1%) cases of grade I, 51
(52.0%) cases of grade II, and 40 (40.8%) cases of grade
III were included in this study. Two (2.0%) cases did not
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were 23 (23.5%), 64 (65.3%), and 11 (11.2%) cases, re-
spectively. For nodal stages, N0 (41 cases, 41.8%) and
N1 (34 cases, 34.7%) were most common. Estrogen re-
ceptor (ER) was positive in 63 cases and progesterone
receptor (PR) was positive in 65 cases (Table 2). ER and
PR positivities of nine cases were not known.
TMEM16A, FADD, and PPFIA1 immunoreactivity
TMEM was positive in 86 cases (strongly positive 5
cases, weakly positive 81 cases). FADD was positive in
62 cases (strongly positive 3 cases, weakly positive 59Table 2 The pathological parameters of the patients


































aNA: not available. LVI, lymphatic vessel invasion; PNI, perineural invasion.cases). PPFIA1 was positive in 88 cases (strongly positive
24 cases, weakly positive 64 cases) (Figure 1). Strongly
positive and weakly positive groups were pooled in the
positive group for association tests and survival analysis.
In association analysis of immunoreactivity of each pro-
tein and pathological parameter, significant association
was only found between FADD expression and T stage
(P = 0.046). Neither TMEM16A nor PPFIA1 showed
significant association with any pathological parameters
studied (Table 3). To see if the expressions of the three
genes are associated, we calculated correlation of coeffi-
cient of each expression. TMEM16A and PPFIA1 ex-
pression was marginally correlated (r = 0.6). However,
FADD expression showed low correlation with PPFIA1
and TMEM16A expression (r = 0.35, each).
Disease-free survival analysis
Survival difference was significant in grade (P = 0.01)
and N stage (P = 0.00) but not in age (P = 0.85) and
T stage (P = 0.189). Both PPFIA1 and TMEM16A ex-
pression showed tendency of association with poor
survival group (P = 0.161 and 0.114, respectively). How-
ever, the survival differences were not strong enough to
show statistical significance. For FADD expression,
positive expression showed a tendency towards bet-
ter survival, but this also failed to show statistical sig-
nificance (P = 0.182).
Combined effect of TMEM16A, PPFIA1, and FADD
expressions
To evaluate net effect of the closely located genes, the
score representing combined effect of the three gene ex-
pressions was calculated and we named it ‘hazard score’.
Because FADD expression showed a tendency towards
better patient survival, we calculated a combined score
using the following equation:
hazard score ¼ TMEM16A scoreþ PPFIA1 score − FADD score
We found the hazard score was associated with peri-
neural invasion status of the cases (Table 3). The cases
with the hazard scores of 2 or more showed significant
association with poor disease-free survival (P = 0.034,
Figure 2).
Discussion
In the current study, we screened the expressions of
TMEM16A, FADD, and PPFIA1 in invasive ductal car-
cinoma of the breast. To see the clinical implications of
these gene expressions, we analyzed the relationship be-
tween the expressions and clinical parameters, including
disease-free survival. As a result, we found that FADD
expression was associated with T stage, showed a combined
score of TMEM16A, FADD, and PPFIA1 expressions and
Figure 1 Representative FADD, TMEM16A, and PPFA1 expression in breast cancer. (A) FADD, negative. (B) FADD, positive. (C) PPFIA1,
negative. (D) PPFIA1, positive. (E) TMEM16A, negative. (F) TMEM16A, positive.
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survival in the invasive ductal carcinoma cases.
According to the previous reports, high expression of
FADD was associated with factors indicating poor prog-
nosis in squamous cell carcinoma of the head and neck
[14,27] and oral squamous cell carcinoma [28]. However,
contradictory clinical associations of FADD expression
were also reported. Colorectal cancer cell growth was
inhibited by FADD expression [29] and high FADD ex-
pression after neoadjuvant breast cancer treatment was
associated with a good prognosis group in breast cancer
[30]. This may be due to the difference in cancer type orprimary site from which the tumor has arisen. We found
that FADD-positive cases showed a tendency towards bet-
ter prognosis, which is concordant with the claim that high
FADD expression is associated with better prognosis in
breast cancer treatment. This also justifies subtraction of
FADD score from the sum of TMEM16A and PPFIA1
scores when we calculate the hazard score of the three
gene expressions in this study. Because the hazard score
was associated with perineural invasion status of invasive
ductal cancer of the breast, we may speculate that combin-
ation of TMEM16A, FADD and PPFIA1 expressions influ-
ence the invasiveness of the tumor cells and affect the
Table 3 TMEM16A, FADD, and PPFIA1 expressions in invasive ductal carcinoma in relation to clinicopathological
parameters (n = number of cases)
TMEM16A FADD PPFIA1 Hazard scorec
+ - P + - P + - P < 2 ≥ 2 P
T stage 0.284 0.046d 0.444 0.069
1 22 1 19 4 22 1 20 3
2 to 3 64 11 43 32 66 9 50 25
N stage 0.756 0.277 1 0.316
0 37 4 29 12 37 4 32 9
1 to 3 49 8 33 24 51 6 38 19
Grade 0.756 0.285 1 0.197
1 to 2 48 8 38 18 50 6 43 13
3 36 4 22 18 36 4 25 15
ER 0.724 0.576 0.439 1.000
0 22 4 15 11 22 4 19 7
1 56 7 42 21 58 5 45 18
PR 0.266 1.000 0.244 0.898
0 19 5 15 9 20 4 18 6
1 to 3 59 6 42 23 60 5 46 19
HER2 1.000 0.918 1.000 0.831
0 46 7 33 20 47 6 37 16
1 to 3 31 4 23 12 32 3 26 9
Age 0.758 1.000 0.723 0.453
< 50 51 8 37 22 54 5 40 19
≥ 50 35 4 25 14 34 5 30 9
LVIa 1.000 0.746 0.716 0.564
0 26 3 17 12 27 2 19 10
1 to 2 58 7 42 23 58 7 48 17
PNIb 0.682 0.077 0.678 0.022a
0 62 9 48 23 63 8 16 55
1 18 1 8 11 18 1 10 9
aLymphatic vessel invasion.
bPerineural invasion.
cHazard score = TMEM16A score + PPFIA1 score – FADD score.
dP < 0.05.
ER, estrogen receptor; HER2, human epidermal growth factor; PR, progesterone receptor.
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lar level is required to confirm this possibility.
PPFIA1 is required for the migration and invasion
of breast cancer cell lines [23]. However, as far as we
know, prognostic significance of PPFIA1 expression in
breast cancer has not been evaluated to date. PPFIA1
amplification was only reported to have significant as-
sociation with poor prognosis in ER-positive cancer and
PPFIA1 expression in terms of prognosis was not stud-
ied [31]. In this study, we showed that PPFIA1 expres-
sion showed a tendency towards an association with poor
prognosis.In addition to PPFIA1, significance of TMEM16A ex-
pression in breast cancer has not been studied to date.
Here, we showed that TMEM16A expression also showed
a tendency towards an association with poor prognosis as
with PPFIA1. Although the individual gene expressions
failed to show statistical significance of association, the
combined effect of TMEM16A, FADD, and PPFIA1 gene
expression was significantly associated with disease-free
survival.
The regulatory mechanism of gene expressions between
PPFIA1, FADD, and TMEM16A is not known. We cannot
explain causal relationship between PPFIA1, FADD, and
Figure 2 Disease-free survivals between groups with different expressions of FADD, PPFIA1, TMEM16A, and hazard score*.
*Hazard score = TMEM16A score + PPFIA1 score – FADD score.
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showed that combined expression status was associated
with the disease-free survival in breast cancer. An explan-
ation for this may be that the three genes located in the
same amplification locus interact each other and influence
tumor cell behavior in breast cancer; this effect resulting in
the difference in disease-free survival.
An evaluation strategy of combining two or more gene
alterations to analyze clinical significance can be found
in several studies on human malignancies. Studies on
the combination effects of two or more gene amplifica-
tions in 11q13 were conducted in oral squamous cell
carcinoma [32] and breast cancer [31]. This method
takes into account possible unknown interactions of
other genes and strengthens statistical power in relatively
small study sizes. Because every single gene expression is
more or less affected by other gene expressions, studies on
combination effects of gene expressions may be closer to
biological phenomenon occurring in vivo than studies on
single gene effects.Conclusion
In summary, we screened TMEM16A, FADD, and PPFIA1
expression in breast cancer and found that combination of
the three gene expressions was associated with disease-free
survival in invasive ductal carcinoma of the breast.
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